TY - JOUR
T1 - Crystal structure of pirfenidone (5-methyl-1-phenyl-1H-pyridin-2-one)
T2 - An active pharmaceutical ingredient (API)
AU - Barbero, Mauro
AU - Mossotti, Matteo
AU - Sironi, Angelo
AU - Giovenzana, Giovanni Battista
AU - Colombo, Valentina
N1 - Publisher Copyright:
© 2019.
PY - 2019
Y1 - 2019
N2 - The crystal structure of pirfenidone, C12H11NO [alternative name: 5-methyl-1-phenylpyridin-2(1H)-one], an active pharmaceutical ingredient (API) approved in Europe and Japan for the treatment of Idiopathic pulmonary fibrosis (IPF), is reported here for the first time. It was crystallized from toluene by the temperature gradient technique, and crystallizes in the chiral monoclinic space group P21. The phenyl and pyridone rings are inclined to each other by 50.30 (11)°. In the crystal, molecules are linked by C-H⋯O hydrogen bonds involving the same acceptor atom, forming undulating layers lying parallel to the ab plane.
AB - The crystal structure of pirfenidone, C12H11NO [alternative name: 5-methyl-1-phenylpyridin-2(1H)-one], an active pharmaceutical ingredient (API) approved in Europe and Japan for the treatment of Idiopathic pulmonary fibrosis (IPF), is reported here for the first time. It was crystallized from toluene by the temperature gradient technique, and crystallizes in the chiral monoclinic space group P21. The phenyl and pyridone rings are inclined to each other by 50.30 (11)°. In the crystal, molecules are linked by C-H⋯O hydrogen bonds involving the same acceptor atom, forming undulating layers lying parallel to the ab plane.
KW - Active pharmaceutical ingredient (API)
KW - Crystal structure
KW - Hydrogen bonding
KW - Idiopathic pulmonary fibrosis (IPF)
KW - Pirfenidone
UR - http://www.scopus.com/inward/record.url?scp=85070009315&partnerID=8YFLogxK
U2 - 10.1107/S2056989019006418
DO - 10.1107/S2056989019006418
M3 - Article
SN - 2056-9890
VL - 75
SP - 984
EP - 986
JO - Acta Crystallographica Section E: Crystallographic Communications
JF - Acta Crystallographica Section E: Crystallographic Communications
ER -